Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lifecore Biomedical, Inc. (LFCR : NSDQ)

• Company Description    Lifecore Biomedical Inc. is a fully integrated contract development and manufacturing organization which offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. Lifecore Biomedical Inc., formerly known as Landec Corporation, is based in CHASKA, Minn. Number of Employees: 406

• Price / Volume Information    Yesterday's Closing Price: $8.18 Daily Weekly Monthly 20 Day Moving Average: 153,813 shares Shares Outstanding: 37.47 (millions) Market Capitalization: $306.48 (millions) Beta: 0.59 52 Week High: $8.85 52 Week Low: $4.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.28% 5.46% 12 Week 23.38% 21.39% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3515 LYMAN BOULEVARD - CHASKA,MN 55318 USA ph: 952-368-4300 fax: 650-368-9818 sdiaz@vidasp.com http://www.lifecore.com

• General Corporate Information    Officers Paul Josephs - President and Chief Executive Officer Katrina L. Houde - Chairman Ryan D. Lake - Chief Financial Officer Humberto C. Antunes - Director Paul H. Johnson - Director Peer Information Lifecore Biomedical, Inc. (CORR.) Lifecore Biomedical, Inc. (RSPI) Lifecore Biomedical, Inc. (CGXP) Lifecore Biomedical, Inc. (BGEN) Lifecore Biomedical, Inc. (GTBP) Lifecore Biomedical, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 514766104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 37.47 Most Recent Split Date: (:1) Beta: 0.59 Market Capitalization: $306.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.27 EPS Growth vs. Year Ago Period: 45.28% vs. Previous Quarter: -190.00% Sales Growth vs. Year Ago Period: 25.92% vs. Previous Quarter: -14.64% ROE 12/31/25 - - 09/30/25 - -1,211.09 06/30/25 - -846.51 ROA 12/31/25 - - 09/30/25 - -10.61 06/30/25 - -13.03 Current Ratio 12/31/25 - - 09/30/25 - 2.80 06/30/25 - 2.84 Quick Ratio 12/31/25 - - 09/30/25 - 1.67 06/30/25 - 1.77 Operating Margin 12/31/25 - - 09/30/25 - -18.97 06/30/25 - -24.76 Net Margin 12/31/25 - - 09/30/25 - -25.59 06/30/25 - -31.70 Pre-Tax Margin 12/31/25 - - 09/30/25 - -22.89 06/30/25 - -29.15 Book Value 12/31/25 - - 09/30/25 - -0.28 06/30/25 - 0.04 Inventory Turnover 12/31/25 - - 09/30/25 - 2.00 06/30/25 - 1.79 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 113.76 Debt-to-Capital 12/31/25 - - 09/30/25 - 81.35 06/30/25 - 76.21

Powered by Zacks Investment Research ©